Assure — Q3 2021 Earnings Presentation
16 slides from Assure's earnings presentation, Nov 15, 2021
Slide 1: 3Q'21 Earnings Call
3Q’21 Earnings Call November 15, 2021 NASDAQ: IONM –TSXV: IOM
Slide 2: Cautionary Note regarding Forward-Looking Statements
Cautionary Note regarding Forward-Looking Statements This presentation may contain “forward-looking statements” within the meaning of applicable securities laws. Forward-looking statements may generally be identified by the use of the words "anticipates," "expects," "intends," "plans," "should," "co
Slide 3: Drivers for Success
Assure Neuromonitoring | 3 Drivers for Success • Awarded three-year agreement to become sole contracted provider of IONM services for Premier, Inc., the second largest GPO in the U.S. • Ramping high margin remote neurology services platform • Organic expansion into new states • Strong potential for
Slide 4: Our Business
Assure Neuromonitoring | 4 Our Business Remote Neurology Services • 1-to-many model • 2,500+ managed cases/year/neurologist * Assure Operations Technologist • 1-to-1 model • Matches board-certified technologist with surgeon in the OR • Each technologist performs ~200 managed cases/year* * See Safe H
Slide 5: Remote Neurology Services Opportunity
Assure Neuromonitoring | 5 Remote Neurology Services Opportunity • Broad platform potential • Margin improvement with scale • Differentiated offering • Adds organic and M&A targets to funnel • Lowers cost of delivery and improves quality of service • Strong potential for expansion into adjacent mark
Slide 6: Remote Neurology Growth Objectives
Remote Neurology Growth Objectives * Based on current run rate 187 716 0 200 400 600 800 1,000 1,200 1,400 2Q'21 3Q'21 4Q'21 Forecast* Number of Remote Neurology Managed Cases** Opportunity • 4 full time neurologists hired • Assure’s remote neurology managed cases expected to increase rapidly for th
Slide 7: Assure Platform
Assure Neuromonitoring | 7 Assure Platform Clinical Operations Revenue Cycle Mgmt. Managed Care Business Operations Accounting/Finance Training & Development M&A IONM Remote Neurology Services Spine Neurosurgery Vascular ENT Orthopedic IONM EEG Epilepsy Sleep Study Stroke Verticals Verticals
Slide 8: Deep Pipeline of Geographic Expansion Opportunities
Deep Pipeline of Geographic Expansion Opportunities Existing Operational Footprint and Targeted States • Expanded into four new states in 2021 • Extending reach within existing states • Numerous M&A opportunities • Extending medical device distributor network that has already facilitated expansion i
Slide 9: Sole Contracted Supplier of IONM Services for Premier, Inc.
Sole Contracted Supplier of IONM Services for Premier, Inc. Assure Neuromonitoring | 9 Premier is the second largest Group Purchasing Organization in the U.S., uniting an alliance of more than 4,400 hospitals and approximately 225,000 other providers • Assure was awarded a 3-year agreement to become
Slide 10: Assure is the Only Publicly Traded Pure-Play IONM Company
Assure is the Only Publicly Traded Pure-Play IONM Company Assure Neuromonitoring | 10
Slide 11: 2021 Corporate Objectives
2021 Corporate Objectives • Increase managed cases* by 70%+ in 2021 • Grow organically by expanding into new states and extending reach in existing states • Pursue M&A opportunities in highly fragmented industry • Accelerate remote neurology platform • Facility-wide outsourcing agreements • Use data
Slide 12: 3Q'21 Financial Highlights (Sequential)
3Q’21 Financial Highlights (Sequential) 4,996 4,257 3,200 3,700 4,200 4,700 5,200 3Q'21 2Q'21 Managed Cases* $8.5 $6.2 $0 $2 $4 $6 $8 $10 3Q'21 2Q'21 Revenue $1.2 -$0.7 ($1.0) ($0.5) $0.0 $0.5 $1.0 $1.5 3Q'21 2Q'21 Adj. EBITDA ** $0.1 -$1.3 ($1.5) ($1.0) ($0.5) $0.0 $0.5 3Q'21 2Q'21 Net Income/Loss
Slide 13: Balance Sheet and Cash Flow Supports Growth Objectives
Balance Sheet and Cash Flow Supports Growth Objectives Capitalization • Strengthened financial position: – $11m credit facility secured with Centurion (Jun ‘21) – $10.5m private placement with Special Situations Funds and Manchester Management as lead investors + mgmt. and board participation (Dec ‘
Slide 14: Q&A
Q&A Assure Holdings 4600 S. Ulster St., Suite 1225 Denver, CO 80237 720-287-3093 www.assureneuromonitoring.com Company Contact John Farlinger Executive Chairman and CEO [email protected] Investor Relations Scott Kozak Director, Investor and Media Relations [email protected] Assure
Slide 15: 3Q'21 Earnings Call - Appendix
3Q’21 Earnings Call - Appendix November 15, 2021 NASDAQ: IONM –TSXV: IOM
Slide 16: Non-GAAP Financial Measures Reconciliation
Non-GAAP Financial Measures Reconciliation Assure Neuromonitoring | 16 2021 2020 2021 2020 (unaudited) (unaudited) (unaudited) (unaudited) Reported net income (loss) 91 $ (977) $ (2,447) $ (14,711) $ Interest expense, net 264 58 500 164 Accretion expense 171 227 386 619 Depreciation and amortization